Table 3.
Baseline demographics and clinical characteristics
| Baseline characteristic | Total population (N = 1997) |
|---|---|
| Female, n (%) | 949 (47.5%) |
| Diabetes duration, years | 7.2 (5.9) [0.2–47.3] |
| Age, years | 56.9 (10.8) [19.0–89.0] |
| Age group, n (%) | |
| 18 to < 45 | 255 (12.8%) |
| 45 to < 65 | 1242 (62.2%) |
| 65 to < 75 | 412 (20.6%) |
| ≥75 | 88 (4.4%) |
| Race, n (%) | |
| White | 1443 (72.3%) |
| Black or African American | 209 (10.5%) |
| Asian | 290 (14.5%) |
| Other | 55 (2.8%) |
| Ethnicity, n (%) | |
| Hispanic or Latino | 366 (18.3%) |
| Not Hispanic or Latino | 1631 (81.7%) |
| Smoking status, n (%) | |
| Current smoker | 324 (16.2%) |
| Previous smoker | 463 (23.2%) |
| Never smoked | 1210 (60.6%) |
| HbA1c, % | 8.2 (1.0) [5.3–14.9] |
| HbA1c group, %, n (%) | |
| <7.0 | 113 (5.7) |
| 7.0 to < 7.5 | 285 (14.3) |
| 7.5 to < 8.0 | 496 (24.8) |
| 8.0 to < 8.5 | 429 (21.5) |
| 8.5 to < 9.0 | 317 (15.9) |
| 9.0 to < 9.5 | 182 (9.1) |
| ≥9.5 | 144 (7.3) |
| Fasting plasma glucose, mmol/L | 9.5 (2.8) [2.4–26.3] |
| Body weight, kg | 94.8 (24.4) [40.3–212.1] |
| BMI, kg/m2 | 33.5 (7.4) [17.2–68.7] |
| BMI group, kg/m2, n (%) | |
| <25 | 193 (9.7) |
| 25 to < 30 | 495 (24.8) |
| 30 to < 35 | 585 (29.3) |
| 35 to < 40 | 391 (19.6) |
| ≥40 | 327 (16.4) |
| Systolic blood pressure, mmHg | 131.3 (14.7) [70.0–202.0] |
| Diastolic blood pressure, mmHg | 79.8 (9.2) [42.0–123.0] |
| Pulse, beats/min | 75.3 (10.3) [45.0–119.0] |
| eGFR, mL/min/1.73 m2 a, n (%) | |
| G 1 (normal) ≥90 | 1109 (55.5) |
| G 2 (mildly decreased) 60–89 | 733 (36.7) |
| G 3 (moderately decreased) 30–59 | 126 (6.3) |
| G 4 (severely decreased) 15–29 | 2 (0.1) |
| Total cholesterol, mg/dL | 176.9 (41.9) [53.3–414.3] |
| LDL cholesterol, mg/dL | 98.1 (35.6) [6.6–291.9] |
| HDL cholesterol, mg/dL | 44.1 (10.9) [18.5–131.3] |
| Triglycerides, mg/dL | 187.2 (128.5) [31.2–2136] |
| Diabetes complications, n (%) [years, range] | 416 (20.8) |
| Diabetic nephropathy | 86 (4.3) [2.7, 0.0–20.1] |
| Diabetic neuropathy | 300 (15.0) [3.8; 0.0–27.5] |
| Diabetic retinopathy | 63 (3.2) [3.0, 0.0–13.5] |
| Macro‐angiopathy | 62 (3.1) [5.2; 0.0–43.3] |
Abbreviations: BMI, body mass index; eGFR, estimated glomerular filtration rate; G, GFR category; HbA1c, glycated haemoglobin; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; n, number of patients; SD, standard deviation.
Data may be subject to minor changes at trial completion after database cleaning. Data are given as arithmetic mean (SD) [min; max] unless otherwise stated.
a
eGFR description and range adapted from Kidney Disease: Improving Global Outcomes (KDIGO) 2012. Kidney Int Suppl. 2013;3:1–150.25